Open Payments by Company
Under the Sunshine Act, drug and device makers must report almost every payment they make to US doctors, nurse practitioners and teaching hospitals: speaking and consulting fees, meals, travel, research money and ownership stakes. CMS publishes it all as Open Payments. This adds it up by company.
What 1,546 drug and device makers reported paying US doctors, other prescribers and teaching hospitals in 2025, and each year back to 2019, under the Physician Payments Sunshine Act. Subsidiaries are rolled up to their parent company where we can match the name.
- Paid in 2025: $14.9B
- Change from 2024: +7%
- General (meals, fees, travel): $3.92B
- Research: $9.50B
- Top 10 companies' share: 42%
Research Payments per Year
Including payments to the institutions running the studies.
General Payments per Year
Consulting and speaking fees, meals, travel, royalties and gifts.
Biggest Payers, 2025
All payment types, by company group.
- Eli Lilly$890M
- Novartis Pharmaceuticals Corporation$738M
- AstraZeneca Pharmaceuticals LP$724M
- AbbVie$648M
- Pfizer$632M
- Amgen$630M
- Biontech SE$559M
- Johnson & Johnson$548M
- Bristol-Myers Squibb$471M
- Roche$471M
Every Company, 2025
Sort by research or by the change from the year before. Companies link to their FDA records.| Eli Lilly4 reporting entities | $890M | $56M | $834M | — | +24% |
| Novartis Pharmaceuticals Corporation2 reporting entities | $738M | $22M | $716M | — | +9% |
| AstraZeneca Pharmaceuticals LP4 reporting entities | $724M | $94M | $631M | — | +23% |
| AbbVie | $648M | $202M | $446M | — | +6% |
| Pfizer9 reporting entities | $632M | $46M | $587M | — | -7% |
| Amgen | $630M | $46M | $585M | — | +84% |
| Biontech SE | $559M | $536M | $22M | — | +173% |
| Johnson & Johnson26 reporting entities | $548M | $180M | $368M | — | -6% |
| Bristol-Myers Squibb3 reporting entities | $471M | $55M | $416M | — | +38% |
| Roche15 reporting entities | $471M | $66M | $405M | — | -7% |
| Merck & Co. (MSD)2 reporting entities | $419M | $25M | $394M | — | -20% |
| Sanofi5 reporting entities | $358M | $77M | $281M | — | +29% |
| Modernatx, Inc. | $335M | $2M | $334M | — | -50% |
| GSK | $306M | $23M | $283M | — | +26% |
| Boehringer Ingelheim Pharmaceuticals, Inc.6 reporting entities | $255M | $20M | $234M | — | +32% |
| Regeneron2 reporting entities | $249M | $40M | $209M | — | +68% |
| Takeda Pharmaceuticals USA | $181M | $46M | $135M | — | -10% |
| Medtronic | $174M | $112M | $63M | — | -8% |
| Vertex Pharmaceuticals | $166M | $10M | $156M | — | +51% |
| Modmed Procure LLC | $160M | $0 | $0 | $160M | New |
| Stryker4 reporting entities | $145M | $136M | $8M | $1M | -8% |
| Boston Scientific3 reporting entities | $141M | $103M | $39M | — | +35% |
| TriMed | $139M | $1M | $0 | $138M | +25% |
| Midmark | $128M | $110K | $0 | $127M | -67% |
| Novo Nordisk4 reporting entities | $120M | $99M | $21M | — | +49% |
| BeOne Medicines8 reporting entities | $119M | $4M | $115M | $394K | +26% |
| Arthrex | $110M | $106M | $4M | — | +1% |
| Abbott Laboratories | $107M | $40M | $67M | — | +17% |
| Zimmer Biomet3 reporting entities | $103M | $91M | $4M | $8M | +11% |
| ViiV Healthcare | $98M | $8M | $90M | — | +152% |
| Incyte Corporation | $97M | $14M | $83M | — | +15% |
| Iti, Inc. | $88M | $17M | $72M | — | +85% |
| Servier2 reporting entities | $86M | $2M | $84M | — | +1% |
| Edwards Lifesciences2 reporting entities | $74M | $22M | $52M | — | -33% |
| Intuitive Surgical2 reporting entities | $72M | $70M | $2M | $549K | -4% |
| Daiichi Sankyo4 reporting entities | $67M | $7M | $60M | — | +33% |
| Advanced Accelerator Applications | $64M | $64M | $0 | — | +1% |
| Cleerly | $63M | $259K | $17M | $46M | +34% |
| CSL2 reporting entities | $62M | $5M | $57M | — | -30% |
| Gilead Sciences | $61M | $36M | $25M | — | -16% |
| Teva Pharmaceutical Industries | $54M | $15M | $39M | — | -19% |
| Longeviti Neuro Solutions | $54M | $727K | $10K | $53M | +53921% |
| Smith & Nephew | $54M | $51M | $3M | — | +7% |
| Eisai2 reporting entities | $52M | $5M | $47M | — | +68% |
| UCB4 reporting entities | $51M | $29M | $22M | — | +28% |
| C2N Diagnostics | $50M | $449K | $12K | $50M | New |
| Imperative Care | $50M | $1M | $1M | $48M | +10% |
| Ipsen6 reporting entities | $48M | $7M | $42M | — | +22% |
| Alnylam Pharmaceuticals | $47M | $8M | $39M | — | +20% |
| Ocular Therapeutix, Inc. | $47M | $2M | $45M | — | +312% |
Eli Lilly
Novartis Pharmaceuticals Corporation
AstraZeneca Pharmaceuticals LP
AbbVie
Pfizer
Amgen
Johnson & Johnson
Bristol-Myers Squibb
Roche
Merck & Co. (MSD)
Sanofi
GSK
Boehringer Ingelheim Pharmaceuticals, Inc.
Takeda Pharmaceuticals USA
Medtronic
Vertex Pharmaceuticals
Stryker
TriMed
Novo Nordisk
BeOne Medicines
Arthrex
Abbott Laboratories
Zimmer Biomet
Incyte Corporation
Edwards Lifesciences
Intuitive Surgical
Daiichi Sankyo
CSL
Gilead Sciences
Teva Pharmaceutical Industries
Longeviti Neuro Solutions
Smith & Nephew
Eisai
UCB
Ipsen
Alnylam PharmaceuticalsCompanies report each payment to doctors, nurse practitioners, physician assistants and other prescribers, and to teaching hospitals; CMS publishes each program year the following June and updates it after disputes and corrections. Research includes payments to the institutions that ran the studies. Ownership is investment and returns held by doctors or their families. Reporting entities are grouped under a parent company by name, so a few may land under the wrong group or none. Data as of 2026-11-14; refreshed weekly. CMS Open Payments, Payments grouped by reporting entities